Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

3(60.0%)

Phase 1

1(20.0%)

Phase 3

1(20.0%)

5Total

N/A(3)

Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT03428477Phase 3Active Not Recruiting

EPA for Metastasis Trial 2

Role: collaborator

NCT05005195Not ApplicableUnknown

Yorkshire Kidney Screening Trial

Role: collaborator

NCT03750110Not ApplicableCompleted

Yorkshire Enhanced Stop Smoking Study

Role: collaborator

NCT02847715Not ApplicableCompleted

Electronic Patient Self-Reported Outcomes to Improve Cancer Management and Patient Experiences

Role: collaborator

NCT03461939Completed

ePRIME: Patient-Reported AEs in Early Phase Trials

Role: collaborator

NCT04509986Unknown

GlobalSurg-CovidSurg Week

Role: collaborator

NCT02882750Completed

Effect on Patient Reported Outcomes of VATS and SABR (LILAC)

Role: collaborator

NCT03282188Phase 1Withdrawn

REO13 Melanoma With of Without GM-CSF

Role: collaborator

NCT02753296Unknown

Development and Evaluation of a Fertility Preservation Patient Decision Aid for Women With Cancer.

Role: collaborator

All 9 trials loaded